Lanzhou Foci Pharmaceutical Co Ltd (SHE:002644) — Market Cap & Net Worth
Market Cap & Net Worth: Lanzhou Foci Pharmaceutical Co Ltd (002644)
Lanzhou Foci Pharmaceutical Co Ltd (SHE:002644) has a market capitalization of $626.94 Million (CN¥4.28 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #11375 globally and #3431 in its home market, demonstrating a 1.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lanzhou Foci Pharmaceutical Co Ltd's stock price CN¥8.39 by its total outstanding shares 510657000 (510.66 Million). Analyse 002644 cash flow metrics to see how efficiently the company converts income to cash.
Lanzhou Foci Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Lanzhou Foci Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.22 Billion to $626.94 Million (-5.60% CAGR).
Lanzhou Foci Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.59x
Lanzhou Foci Pharmaceutical Co Ltd's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.60x
Lanzhou Foci Pharmaceutical Co Ltd's market cap is 9.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.22 Billion | $327.58 Million | $42.95 Million | 3.73x | 28.46x |
| 2016 | $815.03 Million | $363.26 Million | $60.93 Million | 2.24x | 13.38x |
| 2017 | $686.10 Million | $501.14 Million | $74.09 Million | 1.37x | 9.26x |
| 2018 | $564.74 Million | $544.58 Million | $72.92 Million | 1.04x | 7.74x |
| 2019 | $533.15 Million | $628.82 Million | $71.11 Million | 0.85x | 7.50x |
| 2020 | $516.75 Million | $668.05 Million | $108.02 Million | 0.77x | 4.78x |
| 2021 | $742.70 Million | $817.64 Million | $93.26 Million | 0.91x | 7.96x |
| 2022 | $690.94 Million | $1.02 Billion | $108.65 Million | 0.68x | 6.36x |
| 2023 | $725.15 Million | $1.16 Billion | $67.19 Million | 0.62x | 10.79x |
| 2024 | $576.88 Million | $980.23 Million | $60.07 Million | 0.59x | 9.60x |
Competitor Companies of 002644 by Market Capitalization
Companies near Lanzhou Foci Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Lanzhou Foci Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Lanzhou Foci Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Lanzhou Foci Pharmaceutical Co Ltd's market cap moved from $1.22 Billion to $ 626.94 Million, with a yearly change of -5.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥626.94 Million | -2.89% |
| 2025 | CN¥645.63 Million | +11.92% |
| 2024 | CN¥576.88 Million | -20.45% |
| 2023 | CN¥725.15 Million | +4.95% |
| 2022 | CN¥690.94 Million | -6.97% |
| 2021 | CN¥742.70 Million | +43.72% |
| 2020 | CN¥516.75 Million | -3.08% |
| 2019 | CN¥533.15 Million | -5.59% |
| 2018 | CN¥564.74 Million | -17.69% |
| 2017 | CN¥686.10 Million | -15.82% |
| 2016 | CN¥815.03 Million | -33.32% |
| 2015 | CN¥1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Lanzhou Foci Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $626.94 Million USD |
| MoneyControl | $626.94 Million USD |
| MarketWatch | $626.94 Million USD |
| marketcap.company | $626.94 Million USD |
| Reuters | $626.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more